New pill targets Cancer's DNA repair in early trial
NCT ID NCT04991480
Summary
This early-stage study tested a new oral drug called ART4215 in people with advanced or metastatic solid tumors, including breast cancer. The main goals were to find a safe dose for the drug when taken alone and when combined with other cancer drugs, and to check for early signs that it might help control the cancer. The trial did not proceed to later stages to test how well it works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Oklahoma University
Oklahoma City, Oklahoma, 73104, United States
-
Sarah Cannon Research Institute
London, England, UK/W1G 6AD, United Kingdom
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
Yale School of Medicine
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.